Advertisement

Annals of Surgical Oncology

, Volume 21, Issue 4, pp 1107–1114 | Cite as

The Prognostic Significance of an R1 Resection in Gastric Cancer Patients Treated with Adjuvant Chemoradiotherapy

  • Jurriën Stiekema
  • Anouk K. Trip
  • Edwin P. M. Jansen
  • Henk Boot
  • Annemieke Cats
  • Olga Balague Ponz
  • Marcel Verheij
  • Johanna W. van SandickEmail author
Gastrointestinal Oncology

Abstract

Background

A microscopically irradical (R1) resection is a well-known adverse prognostic factor after gastric cancer surgery. However, the prognostic significance of an R1 resection in gastric cancer patients who are treated with chemoradiotherapy (CRT) after the operation has been poorly studied. Therefore, the aim of this study was to evaluate the effect of an R1 resection on (recurrence-free) survival in gastric cancer patients who were treated with CRT after surgery.

Methods

Gastric cancer patients who had undergone a resection with curative intent followed by adjuvant CRT at our institute between 2001 and 2011 were included. CRT consisted of radiotherapy (45 Gy/25 fractions) combined with concurrent capecitabine (with or without cisplatin) or 5-fluorouracil/leucovorin.

Results

A consecutive series of 110 patients was studied, including 80 (73 %) patients who had undergone an R0 resection and 30 (27 %) patients with an R1 resection. Pathologic T-classification (p = 0.26), N-classification (p = 0.77), and histologic subtype according to Laurén (p = 0.071) were not significantly different between these groups. Three-year recurrence-free survival (45 vs. 35 %, p = 0.34) and overall survival (47 vs. 48 %, p = 0.58) did not significantly differ between patients who had undergone an R0 or R1 resection. In a multivariate analysis, pathologic T-classification and N-classification were independent prognostic factors for survival.

Conclusions

A R1 resection was not an adverse prognostic factor in gastric cancer patients who had undergone CRT after the operation.

Keywords

Gastric Cancer Overall Survival Gastric Cancer Patient Locoregional Recurrence Gastric Cancer Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

The authors thank Michael Hauptmann as the statistician who assisted with the statistical analyses.

Funding

Stichting Cornelis Vrolijk Development Fund.

References

  1. 1.
    Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4: survival of cancer patients diagnosed in 1995-1999—results and commentary. Eur J Cancer. 2009;45:931–91.PubMedCrossRefGoogle Scholar
  2. 2.
    Roviello F, Marrelli D, de Manzoni G, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:1113–9.PubMedCrossRefGoogle Scholar
  3. 3.
    D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240:808–16.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.PubMedCrossRefGoogle Scholar
  5. 5.
    Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327–33.PubMedCrossRefGoogle Scholar
  6. 6.
    Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268–73.PubMedCrossRefGoogle Scholar
  7. 7.
    Zhu WG, Xua DF, Pu J, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol. 2012;104:361–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Raziee HR, Cardoso R, Seevaratnam R, et al. Systematic review of the predictors of positive margins in gastric cancer surgery and the effect on survival. Gastric Cancer. 2011;15:116–24.CrossRefGoogle Scholar
  9. 9.
    Morgagni P, Garcea D, Marrelli D, et al. Resection line involvement after gastric cancer surgery: clinical outcome in nonsurgically retreated patients. World J Surg. 2008;32:2661–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Papachristou DN, Agnanti N, D’Agostino H, Fortner JG. Histologically positive esophageal margin in the surgical treatment of gastric cancer. Am J Surg. 1980;139:711–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Sun Z, Li DM, Wang ZN, et al. Prognostic significance of microscopic positive margins for gastric cancer patients with potentially curative resection. Ann Surg Oncol. 2009;16:3028–37.PubMedCrossRefGoogle Scholar
  12. 12.
    Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  13. 13.
    Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma—an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMedGoogle Scholar
  14. 14.
    Jansen EP, Boot H, Dubbelman R, Bartelink H, Cats A, Verheij M. Postoperative chemoradiotherapy in gastric cancer: a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. Br J Cancer. 2007;97:712–6.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Jansen EP, Boot H, Saunders MP, et al. A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys. 2007;69:1424–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Jansen EP, Boot H, Dubbelman R, Verheij M, Cats A. Postoperative chemoradiotherapy in gastric cancer: a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy. Ann Oncol. 2010;21:530–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.PubMedCrossRefGoogle Scholar
  18. 18.
    Wang SY, Yeh CN, Lee HL, et al. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol. 2009;16:2738–43.PubMedCrossRefGoogle Scholar
  19. 19.
    Kim SH, Karpeh MS, Klimstra DS, Leung D, Brennan MF. Effect of microscopic resection line disease on gastric cancer survival. J Gastrointest Surg. 1999;3:24–33.PubMedCrossRefGoogle Scholar
  20. 20.
    Songun I, Bonenkamp JJ, Hermans J, van Krieken JH, van de Velde CJ. Prognostic value of resection-line involvement in patients undergoing curative resections for gastric cancer. Eur J Cancer. 1996;32A:433–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Hofheinz RD, Wenz F, Lukan N, et al. Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer : an extended phase I MARGIT and AIO trial. Int J Radiat Oncol Biol Phys. 2009;73:142–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Kassam Z, Lockwood G, O’Brien C, et al. Conformal radiotherapy in the adjuvant treatment of gastric cancer: review of 82 cases. Int J Radiat Oncol Biol Phys. 2006;65:713–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Hughes BG, Yip D, Chao M, et al. Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experience. Aust N Z J Surg. 2004;74:951–6.CrossRefGoogle Scholar
  24. 24.
    Tsang WK, Leung SF, Chiu SK, et al. Adjuvant chemoradiation for gastric cancer: experience in the Chinese population. Clin Oncol (R Coll Radiol). 2007;19:333–40.PubMedCrossRefGoogle Scholar
  25. 25.
    Chang AT, Ng WT, Law AL, Ku KM, Lee MC, Lee AW. Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. Gastric Cancer. 2011;14:63–71.PubMedCrossRefGoogle Scholar
  26. 26.
    Kundel Y, Purim O, Idelevich E, et al. Postoperative chemoradiation for resected gastric cancer: is the Macdonald regimen tolerable? A retrospective multi-institutional study. Radiat Oncol. 2011;6:127.Google Scholar
  27. 27.
    Lee JH, Ahn SH, Park do J, Kim HH, Lee HJ, Yang HK. Clinical impact of tumor infiltration at the transected surgical margin during gastric cancer surgery. J Surg Oncol. 2012;106:772–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Cheng CT, Tsai CY, Hsu JT, et al. Aggressive surgical approach for patients with T4 gastric carcinoma: promise or myth? Ann Surg Oncol. 2011;18:1606–14.PubMedCrossRefGoogle Scholar
  29. 29.
    Chen JD, Yang XP, Shen JG, Hu WX, Yuan XM, Wang LB. Prognostic improvement of reexcision for positive resection margins in patients with advanced gastric cancer. Eur J Surg Oncol. 2013;39:229–34.PubMedCrossRefGoogle Scholar
  30. 30.
    Dikken JL, Jansen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010;28:2430–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Dikken JL, van Sandick JW, Maurits Swellengrebel HA, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 2011;11:329.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Jurriën Stiekema
    • 1
  • Anouk K. Trip
    • 2
  • Edwin P. M. Jansen
    • 2
  • Henk Boot
    • 3
  • Annemieke Cats
    • 3
  • Olga Balague Ponz
    • 4
  • Marcel Verheij
    • 2
  • Johanna W. van Sandick
    • 1
    Email author
  1. 1.Department of SurgeryThe Netherlands Cancer InstituteAmsterdamThe Netherlands
  2. 2.Department of Radiation OncologyThe Netherlands Cancer InstituteAmsterdamThe Netherlands
  3. 3.Department of Gastroenterology and HepatologyThe Netherlands Cancer InstituteAmsterdamThe Netherlands
  4. 4.Department of PathologyThe Netherlands Cancer InstituteAmsterdamThe Netherlands

Personalised recommendations